Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.

Fiche publication

Date publication

février 2023

Journal

International journal of cardiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Ferreira JP, Cleland JG, Girerd N, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, González A, Diez J, Solomon SD, Claggett B, Pfeffer MA, Pitt B, Petutschnigg J, Pieske B, Edelmann F, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36738846

Résumé

Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by which it acts are uncertain. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate well with histologically proven cardiac fibrosis.